Adjuvant Treatment for Endometrial Cancer – Expert Perspectives
expert roundtables by David Scott Miller, MD, FACOG, FACS; Alexander B. Olawaiye, MD, FRCOG, FACOG, FACS; Pamela T. Soliman, MD, MPH Following surgery for intermediate- to high-risk endometrial cancer, clinicians and patients carefully weigh the risks and benefits of adjuvant therapies. Tumor characteristics used to guide treatment selection for advanced and recurrent endometrial cancer may eventually have a role in the selection of adjuvant therapy. “I tell patients that we could potentially reduce the
